Imagene

About Imagene

Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.

```xml <problem> Traditional molecular cancer testing methods often require extensive tissue samples and can have long turnaround times, delaying treatment decisions. This can lead to patient deterioration while waiting for results, hindering timely access to targeted therapies. </problem> <solution> Imagene AI offers an AI-powered genomic testing solution that analyzes histological data from cancer biopsies to provide rapid, personalized treatment strategies. Their Oncology Intelligence Foundation Model decodes complex tissue patterns to provide actionable insights into disease mechanisms and tumor microenvironments. This enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies. The platform facilitates biomarker discovery to support drug development and advance precision medicine through a transformative SaaS enterprise solution utilizing AI to advance translational research and drive progress in drug development and clinical trials. </solution> <features> - AI-based analysis of histological data from cancer biopsies - Rapid biomarker detection for faster treatment decisions - Oncology Intelligence Foundation Model for diverse oncology applications - Identification of disease mechanisms and tumor microenvironments - Support for biomarker discovery and drug development - Cloud-based platform accessible via Oracle Cloud Infrastructure </features> <target_audience> The primary customers are pharmaceutical companies, medical institutions, and clinical researchers involved in cancer research, drug development, and precision oncology. </target_audience> ```

What does Imagene do?

Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.

Where is Imagene located?

Imagene is based in Miami, United States.

When was Imagene founded?

Imagene was founded in 2020.

How much funding has Imagene raised?

Imagene has raised 21500000.

Location
Miami, United States
Founded
2020
Funding
21500000
Employees
27 employees
Major Investors
Larry Ellison, Eyal Gura

Find Investable Startups and Competitors

Search thousands of startups using natural language

Imagene

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.

imagene-ai.com7K+
cb
Crunchbase
Founded 2020Miami, United States

Funding

$

Estimated Funding

$20M+

Major Investors

Larry Ellison, Eyal Gura

Team (25+)

No team information available.

Company Description

Problem

Traditional molecular cancer testing methods often require extensive tissue samples and can have long turnaround times, delaying treatment decisions. This can lead to patient deterioration while waiting for results, hindering timely access to targeted therapies.

Solution

Imagene AI offers an AI-powered genomic testing solution that analyzes histological data from cancer biopsies to provide rapid, personalized treatment strategies. Their Oncology Intelligence Foundation Model decodes complex tissue patterns to provide actionable insights into disease mechanisms and tumor microenvironments. This enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies. The platform facilitates biomarker discovery to support drug development and advance precision medicine through a transformative SaaS enterprise solution utilizing AI to advance translational research and drive progress in drug development and clinical trials.

Features

AI-based analysis of histological data from cancer biopsies

Rapid biomarker detection for faster treatment decisions

Oncology Intelligence Foundation Model for diverse oncology applications

Identification of disease mechanisms and tumor microenvironments

Support for biomarker discovery and drug development

Cloud-based platform accessible via Oracle Cloud Infrastructure

Target Audience

The primary customers are pharmaceutical companies, medical institutions, and clinical researchers involved in cancer research, drug development, and precision oncology.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.